FDA to Hold Public Hearing on Future of Psychedelic Medicine
Published Date: 7/14/2026
Notice
Summary
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Patient Safety and Informed Consent
FDA seeks input on best practices to promote patient safety for psychedelic therapies, including informed consent topics (e.g., risks of psychological distress and power imbalances), screening for medical and psychiatric risk factors (like cardiovascular disease or psychosis), monitoring during and after administration, and reporting ethical violations. The hearing is on September 14, 2026; comments accepted through October 5, 2026.
Access, Coverage, and Payment Considerations
FDA requests input on access issues for potential therapeutic use of psychedelics, including evidence needs for coverage, benefit design, reimbursement and payment models, coordination between providers and payors, workforce and clinic capacity, and telehealth screening and follow-up. The public hearing is September 14, 2026, and written comments are accepted until October 5, 2026.
Training and Credentialing for Providers
The FDA is asking for public input on provider training and credentialing for supervised psychedelic therapies, including curricula, who should develop or endorse training, staffing needs for screening/administration/follow-up, and credentialing or licensure considerations. The public hearing is September 14, 2026, and comments are accepted until October 5, 2026.
Data Collection and Standardization Plans
FDA is seeking input on best practices for data collection and standardization to assess real-world safety and use of psychedelic drugs, including creation of registries, coordination across data sources (EHRs, claims, pharmacy data, patient- and clinician-reported outcomes), common data elements for drug/dosage/indication, adverse event definitions, interoperability, privacy protections, and longitudinal follow-up. The hearing is September 14, 2026; comments accepted through October 5, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-14154, Hazardous Materials: Notice of Applications for New Special Permits
The Department of Transportation just announced new requests for special permits to handle hazardous materials in different ways. This affects companies that transport dangerous goods by truck, train, ship, or plane, giving them a chance to try new methods safely. If you want to share your thoughts, make sure to comment by August 13, 2026—this could impact how hazardous materials move and possibly save money or time.
Next: 2026-14156, Hazardous Materials: Notice of Actions on Special Permits
The Department of Transportation just updated special permits for companies handling hazardous materials, making some rules clearer and removing outdated parts. This affects businesses shipping dangerous goods, helping them stay safe and compliant without extra costs. If you want to comment, you’ve got until August 13, 2026, so don’t miss your chance!